Covid-19 roundup: Study suggests Omicron variant could escape protection of Pfizer/BioNTech vaccine; Serum Institute prepares launch of Novavax shot for children — report

Nicole DeFeudis

Editor

A new private study by South Africa’s largest insurer, Discovery Health, suggests that Pfizer and BioNTech’s Covid-19 vaccine is just 33% effective against infections by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Study suggests Omicron variant could escape protection of Pfizer/BioNTech vaccine; Serum Institute prepares launch of Novavax shot for children — report

Nicole DeFeudis

Editor

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Bristol Myers sues the federal government over 340B, following other drugmakers

Novartis to cut 139 jobs in NJ as part of commercial refocus

Covid-19 roundup: Study sug­gests Omi­cron vari­ant could es­cape pro­tec­tion of Pfiz­er/BioN­Tech vac­cine; Serum In­sti­tute pre­pares launch of No­vavax shot for chil­dren — re­port

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Covid-19 roundup: Study suggests Omicron variant could escape protection of Pfizer/BioNTech vaccine; Serum Institute prepares launch of Novavax shot for children — report

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Bristol Myers sues the federal government over 340B, following other drugmakers

Novartis to cut 139 jobs in NJ as part of commercial refocus